Wellbeing has closed the opening tranche of its current 2026 capital round. The round remains open at the time of publication. Specific terms, amounts, and participating investors are private and held with Wellbeing’s legal and finance team. This note is Wellbeing’s public acknowledgement that the tranche has closed and that the work the capital supports is now formally funded for the period it covers.
The capital supports the next phase of the research programme. The principal areas of investment are the continued expansion of the clinical-relationship network in the United States and Europe, the continued investment in formal characterisation and documentation work including the white-paper series being published through 2026, and the operating capacity required to support the patient population Wellbeing works with at the scale it operates at today.
Wellbeing is structurally not the kind of organisation that scales aggressively. The capital supports a measured continuation of the operating model Wellbeing has worked under for most of its modern life, with incremental network expansion rather than sudden scaling, continued investment in the science rather than aggressive growth in patient throughput, and the long-arc evidence accumulation that the work fundamentally requires.
Wellbeing does not publish detailed financial information through its news section. Investor and finance-side communication runs through Wellbeing’s investor materials, which are maintained separately by the legal and finance team and shared directly with parties who have a legitimate interest in them. Wellbeing’s working position on this separation is that the news section is for the patient, clinical, and research-community audience, and that financial communication belongs in dedicated channels.
Wellbeing’s leadership remains unchanged through this round. Andrew Chancellor continues as chief executive. Max Lewinsohn continues as chairman. Dr Steve Ray continues as Senior Consultant Scientist. The wider team across the clinical-relationship network, the laboratory side, and the operational and communications side is the team that has been responsible for the work through the past several years.
There is one structural note worth making for the public record. The 2026 round is part of a longer-term funding cadence Wellbeing has been working on through the past several years. Wellbeing has historically been funded through a combination of private investment, patient revenue, and selective philanthropic engagement. The 2026 round continues that pattern rather than representing a change in the funding model. Readers who follow Wellbeing through its press coverage will have seen reference to the 2026 round in several of the late-2025 press features, particularly the TechRound and Founder@ interviews with Andrew Chancellor.
Wellbeing’s working position on capital is the same as its working position on growth. The right amount is whatever amount the work requires, at the pace the work supports, in the structural form that fits the operating model. The 2026 round reflects that working position. Wellbeing does not seek to raise capital beyond what the work needs.
For media or investor enquiries directly related to the round, the appropriate contact is Wellbeing’s legal and finance team rather than this public news section. Patient and clinical enquiries should continue to run through the standard channels published on the contact page. Wellbeing does not, as a matter of standing practice, engage with public commentary on capital raising or financial structure beyond what is in this note.
Wellbeing does not currently expect to publish further capital-related news through 2026 unless and until a further round update is appropriate for the public record.